Abstract:Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.

What problem does this paper attempt to address?

The problems that this paper attempts to solve are related to the latest diagnostic principles, classification updates, prognostic stratification systems, and treatment progress of Myelodysplastic Syndromes/Neoplasms (MDSs). Specifically, the paper focuses on the following aspects: 1. **Diagnostic Principles**: It explores the diagnostic criteria for MDS, including clinical manifestations, morphological features, and genetic criteria. The paper emphasizes the importance of identifying dysplastic cell features and discusses the role of traditional clinical and pathological variables such as blood routine counts, the percentage of bone marrow blasts, and karyotype analysis in risk stratification. 2. **Classification Updates**: It introduces the latest classification updates of MDS in the fifth edition of the World Health Organization (WHO - 5) and the 2022 International Consensus Classification (ICC). These classification systems not only distinguish MDS subtypes with specific genetic abnormalities but also introduce new terms and classification criteria, such as "myelodysplastic neoplasms" replacing "myelodysplastic syndromes", and further subdivide MDS types according to the proportion of blasts. 3. **Prognostic Stratification Systems**: The paper discusses the importance of effective risk stratification for MDS management, especially guiding treatment selection based on the risk of transformation into acute myeloid leukemia (AML). The traditional International Prognostic Scoring System (IPSS) and its revised version (IPSS - R) are widely used, but with the development of genomic sequencing technology, the Molecular International Prognostic Scoring System (IPSS - M), which integrates mutation data, has also emerged, providing more accurate risk assessment. 4. **Treatment Progress**: The paper summarizes the current clinical management strategies for MDS, focusing on different treatment methods for low - risk (LR) and high - risk (HR) MDS. For LR - MDS, it mainly focuses on symptom management and the treatment of cytopenias, especially the treatment of anemia; for HR - MDS, it focuses more on the prevention of disease progression and potential curative treatment. Through the exploration of the above aspects, the paper aims to provide valuable references for future MDS clinical trials and improve the management of adult MDS patients, especially for patients with specific molecular - defined subgroups.

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms